Mielo- i immunotropowe właściwości hormonów grasiczych – zastosowanie kliniczne w hematologii i onkologii
Author(s): Aleksander B Skotnicki
The concept of using the thymominetic drugs in haematology and oncology is based on growing body of evidence of the role of thymus and its hormones in control of immune reactivity. Thymic hormones take part in the immune reaction against several pathogens and are important in recognition and immune attack towards cancer cells expressing neoantigens. The present article describes the results of both experimental and clinical studies of calf thymus extract purified and produced in Poland as Thymus Factor X(TFX)* since 1976. TFX express typical activities of thymic hormones and was found to reveal the therapeutic effectiveness in patients with bone marrow insufficiencies of different origin as well as in patients with several malignant diseases improving their clinical status and prolonging survival. Apart from the results of obtained by Polish authors with TFX the article presents also similar observations performed by American, European and Chinese researchers with other thymominetic preparations.
Share this article
Submitted PhD thesis in Biotechnology at GITAM University, Vizag.
The Past Head, General Administration of Pharmaceutical Care at Ministry of Health,
Saudi Arabia Critical Care/TPN
Clinical Pharmacist Ministry of Health,
Riyadh, Saudi Arabia.
Department of Radiation Oncology
Asahi University Hospital
Gifu city, Gifu, Japan
Maher Abdel Fattah Al-Shayeb
Department of Surgical Sciences, Ajman University, UAE
Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)
Citations : 61
- Euro Pub
- Google Scholar
- Medical Project Poland
- Cancer Index
- Gdansk University of Technology, Ministry Points 20